GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes

TUESDAY, Sept. 17, 2024-- For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for cirrhosis and for cirrhosis...